Model Update after 3Q26 revenues
28/10/26 -"The change in our NAV calculation reflects a change of analyst covering the stock. Our NAV/SOTP valuation is now based on a new breakdown separating the traditional business (Eyecare & Medtech) and ..."
Pages
54
Language
English
Published on
28/10/26
You may also be interested by these reports :
17/11/26
Getinge delivered a mixed Q3 26, with sales marginally below consensus but adjusted EBITA well ahead. ACT drove a sharp margin step-up, even before ...
13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...
13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...
12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...